Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Novel PARP Inhibitor–Based Combinations Targeting Improved Patient Outcomes in Prostate Cancer
  • CME

Charles J. Ryan, MD
Released: April 12, 2021
Back Next

Exploring PARP Inhibitor Combinations in Prostate Cancer

PARP Inhibitor Combinations in Prostate Cancer

In this module, Charles J. Ryan, MD, offers an overview of poly(ADP-ribose) polymerase (PARP) inhibitor therapy in prostate cancer, both as a monotherapy and in novel combination regimens with androgen receptor (AR)–targeted therapies, immunotherapies, and other approaches that may further expand the number of patients with prostate cancer who benefit from PARP inhibitor (PARPi) therapy.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets that can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity, and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

Back Next
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue